Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Nov;26(9):956-63.
doi: 10.1080/07357900802132550.

FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer

Saima Sharif  1 , Michael J O'Connell, Greg Yothers, Samia Lopa, Norman Wolmark
Affiliations
Review

FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer

Saima Sharif et al. Cancer Invest. 2008 Nov.

Abstract

The MOSAIC trial showed that the use of adjuvant oxaliplatin and an infusional regimen of 5-FU/LV in the treatment of stage II/III colon cancer improved disease-free survival (DFS). The NSABP's C-07 trial evaluated the addition of oxaliplatin to a weekly Roswell Park regimen of bolus 5-FU/LV and found a similar improvement in DFS. The benefit of oxaliplatin appears to be independent of the 5-FU/LV regimen used. This paper reviews the efficacy and toxicities of these two regimens and is meant to serve as a guide for clinical practice.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of treatment doses and schedules on MOSAIC and NSABP C-07 (Treatment on both trials was repeated for a maximum duration of 24 weeks)
Figure 2a and Figure 2b
Figure 2a and Figure 2b
Figure 2a. Kaplan-Meier estimate of disease-free survival in the MOSAIC trial. Reproduced with permission from: André, Boni, Mounedji-Boudiaf, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343–51. Copyright© 2004 Massachusetts Medical Society. All rights reserved. Figure 2b: Kaplan-Meier estimate of disease-free survival in the NSABP C-07 trial. Adapted from Figure 2, Kuebler JP et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25 (16), 2007: 2198–2204. Reprinted with permission.
Figure 2a and Figure 2b
Figure 2a and Figure 2b
Figure 2a. Kaplan-Meier estimate of disease-free survival in the MOSAIC trial. Reproduced with permission from: André, Boni, Mounedji-Boudiaf, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343–51. Copyright© 2004 Massachusetts Medical Society. All rights reserved. Figure 2b: Kaplan-Meier estimate of disease-free survival in the NSABP C-07 trial. Adapted from Figure 2, Kuebler JP et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25 (16), 2007: 2198–2204. Reprinted with permission.
See this image and copyright information in PMC

References

    1. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–2947. - PubMed
    1. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet. 2000;355(9209):1041–1047. - PubMed
    1. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of Fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30. - PubMed
    1. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX compared to FOLFOX4: Survival and response results from XELOX-1/NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2007;25(18S) (abstract 4030)
    1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–2342. - PubMed

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources